Cited in:


This article has been cited by:

  1. 1
    François Bailly, Victor Virlogeux, Cécilie Dufour, Pierre Pradat, Christophe Hézode, Dominique Larrey, Laurent Alric, Didier Samuel, Marc Bourlière, Sophie Métivier, Jean-Pierre Zarski, Hélène Fontaine, Véronique Loustaud-Ratti, Lawrence Serfaty, Jean-Pierre Bronowicki, Fabrice Carrat, Fabien Zoulim, Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPIC study, Clinics and Research in Hepatology and Gastroenterology, 2015,


  2. 2
    V. Virlogeux, P. Pradat, F. Bailly, G. Funingana, F. Gonçalves, M. Maynard, K. Hartig-Lavie, M. Amiri, F. Zoulim, Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score, Journal of Viral Hepatitis, 2014, 21, 9